Sanofi Teams Up with Google Life Sciences for Diabetes
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 3:45PM CDT
Sanofi (SNY) and the life sciences team at Google are collaborating for improving care and outcomes for patients with type I and type II diabetes.
GILD: 109.63 (+2.38), GOOGL: 655.30 (+4.22), SNY: 50.23 (+0.46)
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:15PM CDT
Sanofi (SNY) strikes agreements with Evotec and Apeiron Biologics in the area of diabetes and immuno-oncology, respectively.
GILD: 109.63 (+2.38), SNY: 50.23 (+0.46), REGN: 533.30 (+2.08)
How To Beat The Herd Mentality: Highline's Michael Higgins
Life Sciences Report - Seeking Alpha - Thu Feb 26, 2:29PM CST
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't...
BDSI: 7.03 (-0.06), JNJ: 92.93 (+0.21), ESRX: 84.49 (+0.59), PFE: 32.97 (+0.35), PBM: 1.62 (-0.24), GLYC: 7.10 (+0.09), MNKD: 3.70 (-0.05), ALKS: 70.95 (+1.28), PDLI: 5.34 (unch)
Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 5:12PM CST
Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of Orexin-1 selective inhibitors.
JNJ: 92.93 (+0.21), ENDP: 74.80 (-0.43), SNY: 50.23 (+0.46)